Abbott Announces Positive Results in Phase 2 Study of Atrasentan in Treatment of Diabetic Kidney Disease

March 06, 2011

Email this to someoneTweet about this on Twitter0Share on Facebook0Share on Google+0Pin on Pinterest0

Abbott has announced positive results from a Phase 2, 8-week dose-ranging study using low doses of atrasentan in patients with diabetic kidney disease. The results suggest that atrasentan, used in conjunction with renin-angiotensin system (RAS) inhibitors, may reduce albuminuria (presence of protein in urine) for patients with type 2 diabetes. Current standard of care modestly slows the progression of the disease and previous studies with standard of care have shown an association with albuminuria reduction and a slowing of disease progression.

Atrasentan is a highly selective endothelin-A receptor (ETAR) antagonist under investigation as a potential treatment for diabetic kidney disease.

The study results were published in the Journal of the American Society of Nephrology.

Email this to someoneTweet about this on Twitter0Share on Facebook0Share on Google+0Pin on Pinterest0

Add a comment

Your email address will not be published. Required fields are marked *


*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>